| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/27/2005 | WO2004078178B1 Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use |
| 01/27/2005 | WO2004073639A3 Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| 01/27/2005 | WO2004073623A9 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 01/27/2005 | WO2004073584A3 Cystitis treatment with high dose chondroitin sulfate |
| 01/27/2005 | WO2004071459A3 Methods and compositions related to irm compounds and toll-like receptor 8 |
| 01/27/2005 | WO2004069794B1 New arylpiperazinyl compounds |
| 01/27/2005 | WO2004064757A3 Absorption enhancing agents |
| 01/27/2005 | WO2004064747A3 Treating androgen deficiency in female (adif)-associated conditions with sarms |
| 01/27/2005 | WO2004064741A3 Compounds, compositions, and methods |
| 01/27/2005 | WO2004062671A3 Pde4 inhibitors for the treatment of neoplasms of lymphoid cells |
| 01/27/2005 | WO2004060878A3 Inhibitors of phosphatases |
| 01/27/2005 | WO2004043447A3 Compositions and methods for treating or preventing hearing impairment |
| 01/27/2005 | WO2004043381A3 Compositions and methods for prolonging survival of platelets |
| 01/27/2005 | WO2004010998A8 Sustained-release tablet comprising reboxetine |
| 01/27/2005 | WO2003087374A9 Derivatives of the il-2 receptor gamma chain, their production and use. |
| 01/27/2005 | WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase |
| 01/27/2005 | US20050020915 Myocardial perfusion imaging methods and compositions |
| 01/27/2005 | US20050020837 N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
| 01/27/2005 | US20050020836 For therapy of hyperproliferative disorder in a mammal |
| 01/27/2005 | US20050020832 For therapy of atherosclerosis |
| 01/27/2005 | US20050020825 Reacting a D-fructose with CaO to obtain a 2-C-methyl-D-ribonic- gamma -lactone; reducing, coupling with unprotected base such as cytosine in presence of silylating agent |
| 01/27/2005 | US20050020817 Nucleotide sequences coding tumor marker protein for use as tools in detection, prevention a nd treatment of cell proliferative disorders |
| 01/27/2005 | US20050020695 Controlling ligands for regulating fertility and compounds for production of medicine from compounds |
| 01/27/2005 | US20050020694 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 01/27/2005 | US20050020693 Treating a skin growth with a drying agent before surgical removal or treatment with laser or formaldehyde to form gel or powder |
| 01/27/2005 | US20050020692 Injections for treatment of heaves by breathing or injection through skinfor antiinflammatory agents, tablets, capsules, aerosols of racemic mixtures for treatment in horses |
| 01/27/2005 | US20050020691 Pharmaceutical preparations comprising substituted beta-aminoalcohols |
| 01/27/2005 | US20050020690 Infiltration of capsaicin into surgical sites and open wounds |
| 01/27/2005 | US20050020688 Mixing nimesulfide with vinyl glyceol for topical drug for antiinflammatory agents |
| 01/27/2005 | US20050020687 Prevention or treatment of diseases like cancer or inflammation with cytoprotective agents as viricides for infections |
| 01/27/2005 | US20050020686 Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| 01/27/2005 | US20050020684 Modulators of peroxisome proliferator activated receptors |
| 01/27/2005 | US20050020682 Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors |
| 01/27/2005 | US20050020681 Process for producing corosolic acid |
| 01/27/2005 | US20050020679 Enzyme inhibitors for anandamide transporter and pharmacological use with urea, amide, thiourea or other groups |
| 01/27/2005 | US20050020678 Ethyl lactate with fungicide for substrate decontamination |
| 01/27/2005 | US20050020677 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 01/27/2005 | US20050020675 N-[4-cyano-3-(trifluoro-methyl) phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide in crystalline form and amorphous bicalutamide; for use in treatment of prostate cancer |
| 01/27/2005 | US20050020674 Comprising [4-[(N,N-diethylcarbamoyl)methoxy]-3-ethoxyphenyl]acetic acid propyl ester, a water-immiscible solvent, an emulsifier, a tonicity modifier, 0.05-0.2% by weight histidine, and water,wherein pH is greater than 7 and wherein composition contains a preservative |
| 01/27/2005 | US20050020673 reduction; cyclization catalytic hydrogenation |
| 01/27/2005 | US20050020672 Administering compounds selected from 1-phenyl-1,2-propanedione-2-oxime, benzoylacetone, piroctone, 2-furildioxime, 2-furilmonoxime, diethyldithiocarbamic acid, deferoxamine and 1,2-dimethyl-3-hydroxy-pyrid-4-one, or a pharmaceutically acceptable salt or mixtures thereof |
| 01/27/2005 | US20050020671 Core comprises first active ingredient, coating comprising second active ingredient incompatible with first and barrier between core and coating which prevents physical contact between them, characterised in that barrier is formed on core by film-coating and coating is formed by press-coating |
| 01/27/2005 | US20050020670 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofuran |
| 01/27/2005 | US20050020668 Combination comprising S-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl] 2-methylpropanethioate and an HMG CoA reductase inhibitor |
| 01/27/2005 | US20050020667 Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| 01/27/2005 | US20050020666 Cardioprotective agents |
| 01/27/2005 | US20050020665 For example, N-hydroxy-N-(1-benzo[b]thien-2-ylethyl) acetamide,1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxy urea,N-hydroxy-N-(1-benzo[b]thien-2-ylethyl)-N'-methyl urea |
| 01/27/2005 | US20050020663 Improved preparation of alpha -polymorphic eletriptan hydrobromide, by salt formation in a solution of 2-butanone and water, distillation, dehydration, desolventizing; purity, white color crystals |
| 01/27/2005 | US20050020662 Inhibition of PKC to treat permability failure |
| 01/27/2005 | US20050020661 Antidiabetic agents |
| 01/27/2005 | US20050020660 For example, 3-(3-methoxy-1-azabicyclo[2.2.2]oct-3-yl)-1,1-diphenyl-2-propyn-1-ol, 3-[(3R)-3-methoxy-1-azabicyclo [2.2.2]oct-3-yl]-1,1-diphenyl-2-propyn-1-ol; particularly suited for treating urinary incontinence |
| 01/27/2005 | US20050020658 Selective cyclooxygenase-2 inhibitor patch |
| 01/27/2005 | US20050020657 Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 |
| 01/27/2005 | US20050020656 L-histidine, D-histidine, DL-histidine, and/or salts thereof, and optionally cysteine, and/or cystine or salts; fibrosis may be of the kidney, pancreas, lung, vascular vessels, skin, bone marrow, or liver; may be given in foods or beverages |
| 01/27/2005 | US20050020655 Transamination of ondansetron by a Mannich reaction |
| 01/27/2005 | US20050020654 Novel PPAR agonists, pharmaceutical compositions and uses thereof |
| 01/27/2005 | US20050020652 For example, 2-(4-{2-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-ethoxy}-2-methyl-phenoxy)-2-methyl-propionic acid, 2-(4-{3-[1-(4-tert-Butyl-benzyl)-3-methyl-2-oxo-imidazolidin-4-yl]-propyl}-2-methyl-phenoky)-2-methyl-propionic acid; for treating diabetes mellitus |
| 01/27/2005 | US20050020651 Butyric acid derivatives |
| 01/27/2005 | US20050020650 For use as as an antagonist against Leukotriene-B-4 receptor, an inhibitor or therapeutic agent for osteoroposis, thus inhibiting osteolysis and stimulating osteogensis; improving its bioavailability by introducing amino acid residue to the amine |
| 01/27/2005 | US20050020649 Microbicidal composition |
| 01/27/2005 | US20050020647 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome |
| 01/27/2005 | US20050020646 Treating the lower urinary tract symptoms associated with BPH with an antagonist for EP1 receptors, for example, ONO-8711, ONO-8713, 3-{3-[5-chloro-2-(phenylmethoxy)phenyl]2-thienyl}benzoic acid or SC-51089 |
| 01/27/2005 | US20050020642 Antiinflammatory agents; antiarthritic agents; anticancer agents; angiogenesis inhibitors; asthma therapy; cyclooxygenase inhibitor |
| 01/27/2005 | US20050020641 Therapeutic and diagnostic methods dependent on CYP2A enzymes |
| 01/27/2005 | US20050020639 Novel compounds |
| 01/27/2005 | US20050020638 Method of stabilizing lansoprazole |
| 01/27/2005 | US20050020637 Using reverse proton pump inhibitor |
| 01/27/2005 | US20050020636 Antitumor agents |
| 01/27/2005 | US20050020635 C7 carbamoyloxy substituted taxane compositions |
| 01/27/2005 | US20050020634 Acat inhibitors; cardiovascular disorders; restenosis; Alzheimer's disease |
| 01/27/2005 | US20050020633 Nitroxide radioprotector formulations and methods of use |
| 01/27/2005 | US20050020632 Optical isomers of an iloperidone metabolite |
| 01/27/2005 | US20050020631 3-Substituted benzofurans as therapeutic agents |
| 01/27/2005 | US20050020630 Antiinflammatory agents; cardiovascular disorders; anticancer agents; antiarthritic agents; skin disorders; autoimmune disease; cardiovascular disorders |
| 01/27/2005 | US20050020629 Pain management |
| 01/27/2005 | US20050020628 Piperidine derivatives and process for their production |
| 01/27/2005 | US20050020627 Compositions for improving mental concentration |
| 01/27/2005 | US20050020625 Blocking starting compound with metal alkoxide; anticancer agents |
| 01/27/2005 | US20050020624 Dihydroindole and tetrahydroquinoline derivatives |
| 01/27/2005 | US20050020621 Prevent reduced blood flow to brain |
| 01/27/2005 | US20050020618 Antidiabetic agents; obesity |
| 01/27/2005 | US20050020617 3-substituted oxindole beta3 agonists |
| 01/27/2005 | US20050020615 Mixture of rapamycin with tertiary butanol or ethanol; anticancer agents, multiple sclerosis, rheumatic disease |
| 01/27/2005 | US20050020614 Stabilization plaque in blood vessels; therapy for restenosis in diabetic patients |
| 01/27/2005 | US20050020613 Analgesics; time-released; controlling dosage |
| 01/27/2005 | US20050020611 Phosphodiesterase inhibitor; antihistamines; antiallergens |
| 01/27/2005 | US20050020610 Mixture of disaccharides, polysaccharides and solvent |
| 01/27/2005 | US20050020609 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 01/27/2005 | US20050020607 Mixture of 2-(4'-bromobiphenyl-4-sulfonylamino0-3-methylbutyric acid and atorvastatin ; therapy for vascular disorders |
| 01/27/2005 | US20050020604 5-HT receptor ligands and uses thereof |
| 01/27/2005 | US20050020603 Controlling cell proliferation, cell differentiation,autoimmune disease |
| 01/27/2005 | US20050020602 Bone disorders; reduction concentration of parathyroid hormone in blood |
| 01/27/2005 | US20050020600 Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| 01/27/2005 | US20050020599 4-(1,3,4,-thiadiazol-2-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof |
| 01/27/2005 | US20050020598 Antiserotonine agents; central nervous system disorders; anxiolytic agents; cognition activators; schizophrenia ; antidepressants; Alzheimer's disease; Parkinson's disease |
| 01/27/2005 | US20050020597 Attention deficit disorders; hyperactivity; post-trauma stress disorders; anxiolytic agents; obsessive compulsive disorders; analgesics; Parkinson's disease |
| 01/27/2005 | US20050020596 Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands |
| 01/27/2005 | US20050020595 Compounds, methods and pharmaceutical compositions for inhibiting PARP |
| 01/27/2005 | US20050020594 Substituted pyridazinones |
| 01/27/2005 | US20050020593 Anticancer agents |